### **Company Overview** Cipla Limited, founded in 1935, is a leading global pharmaceutical company with a strong presence in over 80 markets across the world. Operating 46 manufacturing facilities globally, Cipla produces more than 1,500 products in over 50 dosage forms, serving patients in diverse therapeutic areas. The company is a pioneer in affordable healthcare innovation, having transformed access to HIV/AIDS treatment in 2001 by launching a low-cost triple antiretroviral therapy in Africa for less than $1 per day. Cipla ranks as the **third-largest pharmaceutical company in India**, the **second-largest in South Africa’s private prescription market**, and the **fourth-largest in the U.S. generic inhalation products segment by prescriptions**. It is also the **second-largest Indian exporter to emerging markets** and the **second-largest global seller of respiratory inhalers** (MDI/DPI). --- ### **Core Therapeutic Strengths** Cipla maintains leadership and growing influence in the following key therapeutic areas: - **Respiratory**: Market leader in India (25% share) and South Africa; 70% dominance in India’s inhalation therapy segment. - **Anti-retroviral (ARV)**: Historic innovator and key supplier to global access programs; significant reach in LMICs via Cipla Global Access (CGA). - **Urology**: Ranked #2 in India. - **Cardiology** - **Anti-infective & Antimicrobial Resistance (AMR)** - **Central Nervous System (CNS)**: Acquired Sanofi’s India CNS portfolio (incl. Frisium®), now ranked #5 in India and strong in South Africa. - **Oncology**: Expanding portfolio with complex generics and biosimilars. - **Diabetes**: Strategic focus via in-licensing (e.g., Novartis’ Galvus), inhaled insulin launch, and combination therapies. **Emerging Growth Frontiers**: - Obesity (GLP-1 agonists) - Wellness (consumer health) - Neurology - Cell & gene therapy - mRNA-based therapeutics --- ### **Business Segments & Global Operations** #### 1. **One India** - Targeting **₹20,000 crores in revenue by FY27–28**, reaching 400 million people. - Branded Prescription: Strong chronic therapy portfolio; brands include **Foracort** (No. 1 pharma brand in IPM, ₹900+ crore revenue), **Dytor**, **Tazact**, **Urimax**, and **Humalog**. - Trade Generics: India’s largest trade generics business, expanding into tier 2–6 towns via GoApptiv platform. - Cipla Health Limited (CHL): Consumer wellness arm; brands include **Nicotex**, **Omnigel**, **Prolyte**, **Cipladine**, and **Cofsils**. #### 2. **SAGA (South Africa and Global Access)** - **South Africa**: - No. 2 in private Rx market; No. 3 in OTC. - Achieved **ZAR 1.65 billion in wellness revenue (FY24–25), up 11.8% YoY**. - Market leader in respiratory and CNS. - Fastest-growing among top 5 OTC players; targets #1 in consumer health. - **Sub-Saharan Africa**: - Revenue grew **18% YoY (USD), with strong contributions from Ghana, Kenya, and Mauritius**. - Market leader in respiratory; >10% share in GI, pain, and respiratory care. - **Cipla Global Access (CGA)**: - Serves 1.5+ million patients in 64 countries. - Key ARV product: **TLD (Tenofovir/Lamivudine/Dolutegravir)**. - Recently launched **pALD (pediatric ARV)**. - Plans to enter **oncology, anti-TB, and reproductive health** in LMICs. #### 3. **North America** - Achieved **record annual revenue of USD 934 million** in FY24–25, up significantly YoY. - U.S. market: - **#1 in generic Albuterol MDI** (21% market share). - **Lanreotide**: 21% market share; key 505(b)(2) success. - **Launched Nilotinib, Nano-Paclitaxel, gAbraxane**, and **Voltido Trio Ciphaler**. - First biosimilar launch planned in **Q2 FY26**. - Pipeline: - Generics of **Advair, Symbicort, Qvar**, and **peptide-based injections**. - 4–5 peptide launches planned over next 2 years. - Manufacturing: - Diversified supply from U.S., India, and strategic partners. - FDA-approved China facility fully operational. #### 4. **Emerging Markets & Europe (EMEU)** - Revenue: **$394 million (FY24–25), up 15% YoY**. - Focus on **deep market penetration in Africa, Middle East, and EU**. - Strong growth in **Morocco (22% YoY), North Africa, and Saudi Arabia**. - Launched **respiratory, GI, diabetes, and biosimilar products**. - Filed over 100 new products in FY24–25 to strengthen pipeline. --- ### **Innovation & R&D Strategy** Cipla is strategically advancing along **three horizons**: - **Horizon 1**: Complex generics, drug-device combos (e.g., Ciphaler, Synchrobreathe). - **Horizon 2**: Biosimilars, peptides, LAIs, 505(b)(2) assets. - **Horizon 3**: Next-gen platforms — mRNA, cell therapy, stem cell, CAR-T. **Key R&D Highlights**: - **R&D investment**: ~5.6% of consolidated revenue. - **1,700+ employees** in R&D across 5 advanced facilities (Maharashtra, Karnataka, New York). - Filed **20 patents, granted 22 in FY24–25**; 2,470+ DMFs submitted globally. - Advanced capabilities in **PBPK modeling, CFD, nanotechnology, and oligonucleotide synthesis**. --- ### **Product & Pipeline Developments (2025 Focus)** #### **Respiratory** - **Differentiated launch**: *Voltido Trio Ciphaler* (triple-combo therapy). - Dedicated **respiratory division** established for enhanced launch performance. - Pipeline includes **gAdvair, gSymbicort, Fluticasone Salmeterol DPI**, and **Tiotropium DPI**. - Developing **26 combo products** based on Ciphaler/Synchrobreathe platforms. - Pioneering **low-GWP propellants** for environmentally sustainable inhalers. #### **Oncology** - Launched **Nilotinib (505(b)2), Nano-Paclitaxel, gAbraxane, Leuprolide**. - **Plazomicin** launched in India for complicated UTIs. - Pipeline includes **semaglutide for obesity**, biosimilars, and oligonucleotides. #### **Biosimilars & Peptides** - Joint venture with **Kemwell Biopharma & Aspergen Inc.** advancing biosimilar development. - **ASP-100 (biosimilar)** to enter clinical trials in FY25–26. - Two biosimilar assets in development; first U.S. biosimilar launch expected Q2 FY26. - Multiple **peptide injectables** launched with **CGT exclusivity**. #### **Diagnostic & Digital Health** - **CipAir**: AI-powered asthma screening app (launched in India). - **Spirofy**: Handheld spirometer; deployed in India, Nepal. - **Cippoint**: Multiparameter point-of-care diagnostic device. - **CipOscillo®**: Portable oscillometer for airway obstruction (license filed). - **Breathefree App**: 1.5+ million downloads; digital support for asthma/COPD patients. --- ### **Strategic Acquisitions & Partnerships** - **Acquired**: - **Sanofi’s India CNS portfolio**. - **Actor Pharma (South Africa)** – enhanced OTC presence. - **Ivia Beaute Pvt. Ltd.** – strengthened wellness brands (Astaberry, Ikin, Bhimsaini). - **Endura Mass** – entry into nutrition segment. - **Partnerships**: - **Ethris GmbH (mRNA)**: Co-developing for India and LMICs; building Centre of Excellence in Europe. - **MannKind Corporation**: Inhaled insulin **Afrezza®** launched in India. - **Formosa Pharmaceuticals**: Multi-region ophthalmic treatment. - **Takeda**: **Vonoprazan** for acid reflux. - **Orchid Pharma**: **Cefepime+Enmetazobactam** for AMR. - **CSIR-CDRI**: Fungal keratitis drug co-development. - **GoApptiv**: Expanding phygital access to Tier 2–6 markets in India. --- ### **Manufacturing & Supply Chain Strength** - 46 cGMP-compliant manufacturing sites across India, USA, South Africa, China, Morocco, Uganda. - **Backward integration** in API: 200+ APIs produced, supplied to 250+ global customers. - **Industry 4.0 adoption**: 15+ use cases; Indore facility designated a **WEF Advanced 4IR Lighthouse**. - Supply network diversified: **1/3 U.S., 1/3 India, 1/3 partners**. - **FDA-approved China plant** now fully utilized for respules supply. --- ### **ESG & Sustainability** - Pioneered **low-GWP propellants** in inhalers. - Reduced lead time and extended shelf life of TLD formulation. - Industry 4.0 and smart manufacturing drive **resource efficiency**. - Strong advocacy for **affordable medicines**, access, and equitable healthcare. ---